Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | P2RX3 | P56373 | 12/20 | 0.47 |
| ▸ | P2RX2 | Q9UBL9 | 12/20 | 0.47 |
| ▸ | GCK | P35557 | 2/20 | 0.43 |
| ▸ | ACACB | O00763 | 3/20 | 0.42 |
| ▸ | ACACA | Q13085 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9898647 | 0.96 | NPC1 (0.49) | NPC1ALDH1A1RAB9ASMN1; SMN2P2RX3 | |
| SCHEMBL9898826 | 0.95 | P2RX3 (0.51) | NPC1ALDH1A1RAB9ASMN1; SMN2P2RX3 | |
| SCHEMBL1271074 | 0.87 | RAB9A (0.44) | NPC1ALDH1A1RAB9ASMN1; SMN2P2RX3 | |
| SCHEMBL2726157 | 0.87 | GCK (0.53) | GCK | |
| SCHEMBL9898774 | 0.86 | NPC1 (0.43) | NPC1ALDH1A1RAB9ASMN1; SMN2P2RX3 | |
| SCHEMBL9899287 | 0.86 | GRM5 (0.51) | NPC1RAB9ASMN1; SMN2GCK | |
| SCHEMBL9898678 | 0.86 | GCK (0.44) | NPC1ALDH1A1RAB9ASMN1; SMN2GCK | |
| SCHEMBL2724685 | 0.84 | GCK (0.41) | NPC1ALDH1A1RAB9ASMN1; SMN2GCK | |
| SCHEMBL9900287 | 0.84 | GCK (0.51) | GCK | |
| SCHEMBL2724909 | 0.84 | GCK (0.54) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450494-B2 | Disubstituted benzamide derivatives as glucokinase (GK) activators | CADILA HEALTHCARE LIMITED (IN) | 2013-05-28 | — | — | US | disclosed |
| US-20120149704-A1 | DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | CADILA HEALTHCARE LIMITED (IN) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149704-A1 | DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | GCKR, GCK, GK | NPC1 1754/4885ALDH1A1 958/4885RAB9A 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.